Biogen pushes back its timeline on the big aducanumab FDA filing as Covid-19 slows work — shares wilt
You can scratch off an early 2020 aducanumab filing from your list of Biogen catalysts.
The big biotech $BIIB reported Wednesday morning that it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
